Limits...
A case of advanced malignant pleural mesothelioma treatment with chemotherapy and photodynamic therapy.

Ryu JW, Kim YS - Tuberc Respir Dis (Seoul) (2015)

Bottom Line: Our patient received chemotherapy using pemetrexed/cisplatin.Afterwards, he received a single PDT treatment and then later took chemotherapy using gemcitabine/cisplatin.The patient showed a survival time of 27 months, which is longer than median survival time in advanced MPM patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic and Cardiovascular Surgery, Dankook University College of Medicine, Cheonan, Korea.

ABSTRACT
Malignant pleural mesothelioma (MPM) is an aggressive, treatment-resistant, and generally fatal disease. A 68-year-old male who was diagnosed with MPM at another hospital came to our hospital with dyspnea. We advised him to take combination chemotherapy but he refused to take the treatment. That was because he had already received chemotherapy with supportive care at another hospital but his condition worsened. Thus, we recommended photodynamic therapy (PDT) to deal with the dyspnea and MPM. After PDT, the dyspnea improved and the patient then decided to take the combination chemotherapy. Our patient received chemotherapy using pemetrexed/cisplatin. Afterwards, he received a single PDT treatment and then later took chemotherapy using gemcitabine/cisplatin. The patient showed a survival time of 27 months, which is longer than median survival time in advanced MPM patients. Further research and clinical trials are needed to demonstrate any synergistic effect between the combination chemotherapy and PDT.

No MeSH data available.


Related in: MedlinePlus

(A) The pleural mass. (B) Photodynamic therapy taking place. Laser light is being delivered into the pleural cavity via the optical fiber. (C) Necrotic changes on the pleural surface after photodynamic therapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4311034&req=5

Figure 3: (A) The pleural mass. (B) Photodynamic therapy taking place. Laser light is being delivered into the pleural cavity via the optical fiber. (C) Necrotic changes on the pleural surface after photodynamic therapy.

Mentions: To perform PDT, photosensitizer used for the patient is photogem (Lomonosov Institute of Fine Chemical, Moscow, Russia), and 2.5 mg/kg was injected through intravenous 48 hours before the procedure. To prevent complications due to skin photosensitive reaction, the patient was advised to avoid direct light for 48 hours. After that, under general anesthesia the patient had thoracoscope inserted after posterolateral thoracotomy. As a light delivery device, flexible cylindrical fiber was used, and diode laser system (Biolitec, Jena, Germany) was employed based on 632 nm wavelength, with 15 J/cm2 light doses being applied (Figure 3A-C). Following PDT, light shield was carried out to avoid sun light. After PDT, dyspnea improved and complications were not observed. Once his symptom and general condition got better, he changed his mind and decided receive chemotherapy.


A case of advanced malignant pleural mesothelioma treatment with chemotherapy and photodynamic therapy.

Ryu JW, Kim YS - Tuberc Respir Dis (Seoul) (2015)

(A) The pleural mass. (B) Photodynamic therapy taking place. Laser light is being delivered into the pleural cavity via the optical fiber. (C) Necrotic changes on the pleural surface after photodynamic therapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4311034&req=5

Figure 3: (A) The pleural mass. (B) Photodynamic therapy taking place. Laser light is being delivered into the pleural cavity via the optical fiber. (C) Necrotic changes on the pleural surface after photodynamic therapy.
Mentions: To perform PDT, photosensitizer used for the patient is photogem (Lomonosov Institute of Fine Chemical, Moscow, Russia), and 2.5 mg/kg was injected through intravenous 48 hours before the procedure. To prevent complications due to skin photosensitive reaction, the patient was advised to avoid direct light for 48 hours. After that, under general anesthesia the patient had thoracoscope inserted after posterolateral thoracotomy. As a light delivery device, flexible cylindrical fiber was used, and diode laser system (Biolitec, Jena, Germany) was employed based on 632 nm wavelength, with 15 J/cm2 light doses being applied (Figure 3A-C). Following PDT, light shield was carried out to avoid sun light. After PDT, dyspnea improved and complications were not observed. Once his symptom and general condition got better, he changed his mind and decided receive chemotherapy.

Bottom Line: Our patient received chemotherapy using pemetrexed/cisplatin.Afterwards, he received a single PDT treatment and then later took chemotherapy using gemcitabine/cisplatin.The patient showed a survival time of 27 months, which is longer than median survival time in advanced MPM patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic and Cardiovascular Surgery, Dankook University College of Medicine, Cheonan, Korea.

ABSTRACT
Malignant pleural mesothelioma (MPM) is an aggressive, treatment-resistant, and generally fatal disease. A 68-year-old male who was diagnosed with MPM at another hospital came to our hospital with dyspnea. We advised him to take combination chemotherapy but he refused to take the treatment. That was because he had already received chemotherapy with supportive care at another hospital but his condition worsened. Thus, we recommended photodynamic therapy (PDT) to deal with the dyspnea and MPM. After PDT, the dyspnea improved and the patient then decided to take the combination chemotherapy. Our patient received chemotherapy using pemetrexed/cisplatin. Afterwards, he received a single PDT treatment and then later took chemotherapy using gemcitabine/cisplatin. The patient showed a survival time of 27 months, which is longer than median survival time in advanced MPM patients. Further research and clinical trials are needed to demonstrate any synergistic effect between the combination chemotherapy and PDT.

No MeSH data available.


Related in: MedlinePlus